International task force charts path to precision stroke recovery through biomarkers

A stroke survivor leaves the hospital after weeks of acute care. Physical therapy begins. Speech therapy follows. Occupational therapy fills the gaps. The patient works hard, shows some improvement, plateaus. But nobody really knows if they're getting the right amount of therapy, at the right time, delivered in the right way. And nobody knows why some brains bounce back while others don't.

This gap in understanding—fundamental and frustrating—is what an international task force has now set out to close. Led by Matthew Edwardson, a neurologist and rehabilitation specialist at Georgetown University, the group has published a roadmap in the International Journal of Stroke that positions molecular biomarkers as the key to unlocking precision stroke recovery. The framework represents a significant shift in how the field thinks about what happens after a stroke, moving from treating recovery as an outcome to studying it as a biological process.

The problem is real and widespread. After a stroke, patients typically receive occupational, physical, or speech therapy—interventions that the field broadly agrees are beneficial. But that consensus masks profound uncertainty. How much therapy is actually optimal? When should it start? Which delivery method works best for which patient? These questions remain largely unanswered because the tools to measure what's happening inside the brain during recovery have been inadequate. Blood biomarkers—molecular signatures that could reveal how the brain is repairing itself—have barely been explored in stroke recovery, despite transforming other fields of medicine. Cardiovascular disease, for instance, now benefits from individualized antiplatelet regimens and targeted lipid-lowering therapies driven by molecular insights. Stroke recovery has no such precision tools.

The lag is not accidental. Edwardson and his colleagues identified multiple structural barriers. Recovery studies are logistically brutal: patients must be tracked not just at hospital discharge but at one month, three months, and six months afterward—often across different settings like nursing facilities or home care. Traditional rehabilitation studies are expensive because therapists must deliver care over weeks. And pharmaceutical companies have invested little in the recovery phase, leaving few large-scale studies in the pipeline. Most earlier research happened at single centers with small patient populations, blood drawn at only one time point, and inconsistent outcome measures. The statistical power needed to make real discoveries simply wasn't there.

The task force's central recommendation is deceptively simple: standardize. Larger international studies should collect blood samples at the same time points for every patient, measure the same outcomes—including specific deficits like arm weakness, speech problems, or cognitive decline—and analyze the data rigorously across different geographic and ethnic populations. This will require investment: funding for the studies themselves, infrastructure for biorepositories to store samples across continents, and expertise to guide researchers who want to participate. The task force estimates that meaningful discoveries in genomics typically require sample sizes in the thousands, not hundreds.

But the roadmap includes a crucial safeguard. During consultations with other experts, the task force found widespread concern that biomarkers predicting poor recovery could be weaponized—used by insurance companies to deny rehabilitation care to patients deemed unlikely to improve. The task force was explicit: biomarkers should never be used to ration resources or deny access. Their purpose is to understand the biology of stroke so that new treatments can be developed, not to make triage decisions based on molecular predictions.

Edwardson's own work continues in this direction. He and colleagues at Georgetown's Center for Brain Plasticity and Recovery recently received a Thomas A. Reynolds III Return to Function Challenge Grant to study circulating molecular biomarkers during stroke recovery. The next phase, he says, is rigorous validation in larger patient populations—work that could lay the foundation for an era of personalized stroke rehabilitation, where treatment is tailored not to a generic protocol but to what a patient's own biology reveals about their capacity to heal.